The main objective of this study is to determine whether neoadjuvant chemotherapy with cisplatin and paclitaxel plus standard cisplatin-based chemoradiation with extended fields improves progression free survival rates compared to chemoradiation therapy alone in locally advanced cervical cancer. Women in the experimental arm will receive neoadjuvant chemotherapy with cisplatin and paclitaxel every 21 days during 2 cycles followed by concurrent chemoradiation therapy. Women in the control arm will receive concurrent chemoradiation therapy alone. 286 patients will be recruited during 2 years,with 3 years of follow up period.